IL-31 induces antitumor immunity in breast carcinoma

Keyphrases

• Breast Carcinoma 100%
• Tumor Immunity 100%
• IL-31 100%
• Tumor 20%
• CD4+ T 13%
• Recombinant 13%
• Interleukin-4 (IL-4) 13%
• Cytotoxic T Cells 13%
• Improved Survival 6%
• Therapeutic Potential 6%
• Interleukin 6%
• Cell Proliferation 6%
• Breast Cancer 6%
• Growth Rate 6%
• Interleukin-6 6%
• Cancer Treatment 6%
• Human Breast Cancer 6%
• Cell-Associated 6%
• Tumor Microenvironment 6%
• Interleukin-2 6%
• In Vitro Study 6%
• Immunomodulatory Effect 6%
• GATA3 6%
• T Cell Activation 6%
• High-level Expression 6%
• CD4+ 6%
• Cell Activity 6%
• Breast Cancer Biopsy 6%
• Cell Motility 6%
• Immune Cells 6%
• Inflammatory Cytokines 6%
• Antitumor 6%
• Immunomodulation 6%
• CD8+ T Cell Infiltration 6%
• Co-expression 6%
• Cellular Changes 6%
• Antiangiogenic Agents 6%
• Tumor-associated Macrophages 6%
• Comparisons with a Control 6%
• EMT6 6%
• Cytokine Profile 6%
• Antitumor Therapeutics 6%
• Linker Region 6%
• Immunological Activity 6%
• Mouse Data 6%
• Interleukin-31 Receptor 6%
• Suppressor Macrophages 6%
• PyMT 6%
• Data Alteration 6%

Immunology and Microbiology

• Interleukin 31 100%
• Myeloid-Derived Suppressor Cell 18%
• Cytokine 12%
• T-Helper Cell 12%
• Cell Activity 12%
• Interleukin 4 12%
• Immunocompetent Cell 12%
• Cytotoxic T Cell 12%
• Cell Line 6%
• CD4 6%
• Cell Proliferation 6%
• Murine 6%
• Macrophage 6%
• Tumor-Associated Macrophage 6%
• Interleukin 2 6%
• Transcription Factor GATA 3 6%
• Interleukin 6 6%
• Cytotoxic T-Cell 6%
• Immunomodulation 6%
• T Cell Activation 6%
• Proinflammatory Cytokine 6%
• Angiogenesis Inhibitor 6%
• Vertebral Column 6%
• Cell Composition 6%
• Th0 Cell 6%